ArticleBMC medicine2022
Links between electroconvulsive therapy responsive and cognitive impairment multimodal brain networks in late-life major depressive disorder.
Article in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02999269 (ECT Pulse Amplitude and Medial Temporal Lobe Engagement), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ECT Pulse Amplitude and Medial Temporal Lobe Engagement
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations in Schizophrenia: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Network Pharmacology Reveals the Potential Mechanism of Ketamine in Improving Cognitive Impairment in Patients With Depression.Alpha psychiatry · 2026Article
- Article
- Cranial Sutures Alter Computational Models of Transcranial Electrical Stimulation.The journal of ECT · 2026Article
- A Computational Modeling Study of Focal Electrically Administered Seizure Therapy and Frontoparietal Electroconvulsive Therapy.The journal of ECT · 2026Article
- Functional connectivity differences in patients with mood disorders: an exploratory fMRI study comparing electroconvulsive therapy with pharmacological treatment.Neuroscience applied · 2025Article
- Associations of alcohol and tobacco use with psychotic, depressive and developmental disorders revealed via multimodal neuroimaging.Translational psychiatry · 2024Article
- Amplitude-determined seizure-threshold, electric field modeling, and electroconvulsive therapy antidepressant and cognitive outcomes.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- The heterogeneity of late-life depression and its pathobiology: a brain network dysfunction disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
- Correction: Links between electroconvulsive therapy responsive and cognitive impairment multimodal brain networks in late-life major depressive disorder.BMC medicine · 2023Article
- Data-driven multimodal fusion: approaches and applications in psychiatric research.Psychoradiology · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundAlthough electroconvulsive therapy (ECT) is an effective treatment for depression, ECT cognitive impairment remains a major concern. The neurobiological underpinnings and mechanisms underlying ECT antidepressant and cognitive impairment effects remain unknown. This investigation aims to identify ECT antidepressant-response and cognitive-impairment multimodal brain networks and assesses whether they are associated with the ECT-induced electric field (E-field) with an optimal pulse amplitude estimation.
methodsA single site clinical trial focused on amplitude (600, 700, and 800 mA) included longitudinal multimodal imaging and clinical and cognitive assessments completed before and immediately after the ECT series (n = 54) for late-life depression. Another two independent validation cohorts (n = 84, n = 260) were included. Symptom and cognition were used as references to supervise fMRI and sMRI fusion to identify ECT antidepressant-response and cognitive-impairment multimodal brain networks. Correlations between ECT-induced E-field within these two networks and clinical and cognitive outcomes were calculated. An optimal pulse amplitude was estimated based on E-field within antidepressant-response and cognitive-impairment networks.
resultsDecreased function in the superior orbitofrontal cortex and caudate accompanied with increased volume in medial temporal cortex showed covarying functional and structural alterations in both antidepressant-response and cognitive-impairment networks. Volume increases in the hippocampal complex and thalamus were antidepressant-response specific, and functional decreases in the amygdala and hippocampal complex were cognitive-impairment specific, which were validated in two independent datasets. The E-field within these two networks showed an inverse relationship with HDRS reduction and cognitive impairment. The optimal E-filed range as [92.7-113.9] V/m was estimated to maximize antidepressant outcomes without compromising cognitive safety.
conclusionsThe large degree of overlap between antidepressant-response and cognitive-impairment networks challenges parameter development focused on precise E-field dosing with new electrode placements. The determination of the optimal individualized ECT amplitude within the antidepressant and cognitive networks may improve the treatment benefit-risk ratio.
trial registrationClinicalTrials.gov Identifier: NCT02999269.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.